

SCIENTIFIC DIVISION

44th MEETING
Milan, IT (2009 10 2-3)
MINUTES (*final draft*)

Members:	Abbr.	Term and Time of Office	
Mauro PANTEGHINI (IT) (Chair)	MP	2 nd	2009 01 - 2011 12
Ian YOUNG (UK) (Vice-Chair)	IY	2 nd	2009 01 - 2011 12
Gary MYERS (US) (Secretary)	GM	1 st	2009 01 - 2011 12
Philippe GILLERY (FR)	PG	2 nd	2009 01 - 2011 12
Lothar SIEKMANN (DE)	LS	2 nd	2009 01 - 2011 12
Naotaka HAMASAKI (JP)	NH	1 st	2009 01 - 2011 12
George BROTEA (US) (Corporate Representative)	GB	1 st	2007 01 - 2009 12
David BUNK (NIST Representative)	DB		Consultant
Heinz SCHIMMEL (IRMM Representative)	HS		Consultant
Jean-Claude FOREST (JCTLM Representative)	JCF		Consultant

EXECUTIVE SUMMARY - SCIENTIFIC DIVISION 44th MEETING, MILAN, ITALY OCTOBER 2 & 3, 2009.

Present: Mauro Panteghini (Chair), Ian Young (Vice-Chair), Gary Myers (Secretary), Philippe Gillery, Lothar Siekmann, Naotaka Hamasaki, George Brotea (Corporate Representative), and Jean-Claude Forest (JCTLM Representative) with Ms Paola Bramati (IFCC Office) were in attendance. Apologies from David Bunk (NIST Representative) and Heinz Schimmel (IRMM Representative)

6.1 WORLD HEALTH ORGANIZATION (WHO): The WHO *Expert Committee on Biological Standardization (ECBS)* will meet in October 2009. Jean-Claude Forest will attend on behalf of the IFCC. Of interest to IFCC will be the submission of the reference material for hCG and also a new lot (SP3-08) of apolipoprotein B reference material.

6.2 CLSI: As of July 2009, a total of 23 IFCC/CLSI joint projects have been completed or are in progress.

6.22.1 JCTLM: The meeting of JCTLM WG-1 and WG-2 was held July 18, 2009 in conjunction with the AACC Annual Meeting in Chicago, IL.

The paper on “*Criteria to assess the quality of nominated nucleic acid reference materials with stated nominal properties*” developed by the Review Team for Nucleic Acids had been approved by the JCTLM Executive in April 2009. JCF will complete his tenure as JCTLM Executive Committee Chair at the end of 2009.

6.22.2 JCGM: WG 1 (GUM) next meeting: 10-13 November 2009, Cape Town, South Africa.

WG 2 (VIM) met at BIPM on September 2-4, 2009. The objective is to publish the Corrigenda Sheets (one for each of the three published versions of VIM3) by the end of 2009. Then, there will be only one version of VIM3, which will be the JCGM version. The timetable for publication of VIM4 is in about 10 years. Next meeting: 30 Nov.–1 Dec., 2009.

6.22.3 CCQM: The 15th meeting of the CCQM was held on 22-24 April 2009. In an attempt to try to develop an analytical connection between the two assessment schemes, CCQM key comparisons (only for NMIs) and the IFCC RELA, the CCQM NMIs were invited to participate in the IFCC program. The offer was taken under consideration by the CCQM.

6.31 INSTITUTE FOR REFERENCE MATERIALS AND MEASUREMENTS (IRMM):

The reference material ERM-DA457/IFCC AST has been released.

6.37 NATIONAL INSTITUTE FOR STANDARDS AND TECHNOLOGY (NIST):

A NIST/JCTLM/CCQM Workshop: “Measurement and standards needs for next generation healthcare delivery” was held at the AACC meeting in Chicago, IL (US) 19 July 2009.

8.2 MAIN ACTIVITIES OF COMMITTEES:

8.2.6 C-NPU: A meeting of C-NPU was held 3-4 August 2009 in Glasgow, UK. The pilot trial to assess the ability for SNOMED-CT to work effectively in combination with either LOINC or NPU terminologies was completed. Results from the pilot project will be evaluated at an IHTSDO meeting in Washington, 1-3 October 2009.

8.2.11 C-MD: The C-MD met June 2009 in Innsbruck, Austria. The C-MD published the following opinion paper: “Considerations for the development of a reference method for sequencing of haploid DNA- an opinion paper on behalf of the IFCC Committee on Molecular Diagnostics/International Federation of Clinical Chemistry and Laboratory Medicine” Clin Chem Lab Med 2009:47 (November issue). Nominations remain open to join the networks of IFCC Expert Molecular Diagnostics Centres and Member Laboratories

8.2.13 C-PP: The C-PP met June 2009 in Innsbruck, Austria. The C-PP Chair attended the SD meeting on 3 October 2009 to update members of SD on Committee activities. SD recommended that C-PP focus on 2 projects that can be completed by the end of 2010: 1. β 2-microglobulin certification of ERM-DA470k/IFCC material and 2. analytical and clinical evaluation of serum free light chain measurement.

8.2.19 C-SMCD: The C-SMCD met in conjunction with the AACC annual meeting July 2009 in Chicago, IL (US). The tables for cardiac troponin and natriuretic peptides assays have been reviewed, updated and submitted for posting on IFCC website.

8.2.21 C-RSE: The C-RSE met June 2009 in Innsbruck, Austria. The manuscript of the primary reference measurement procedure for alkaline phosphatase (ALP) will be ready for submission to the IFCC SD as soon as reference intervals are provided by C-RIDL.

8.2.23 C-TLM: The C-TLM met June 2009 in Innsbruck, Austria. The list of National Accreditation Bodies has been updated and is available for download on the JCTLM website. The deadline for demonstrating accreditation will probably be extended to the end of 2010. A recommended additional requirement to the

criteria for listing a reference laboratory by JCTLM will be that each laboratory must participate with each measurand to the IFCC RELA at least once in three years.

8.2.24 C-RIDL: The C-RIDL met June 2009 in Innsbruck, Austria. Results from reference interval study for ALP have been sent to the C-RSE. Results from the AST, ALT, GGT reference interval study will be published as soon as possible.

8.3 MAIN ACTIVITIES OF WORKING GROUPS:

8.3.16 WG-SHCG: The WG-SHCG met June 2009 in Innsbruck, Austria. The paper summarizing results obtained by different hCG commercial assays with the international reference reagents for hCG and related molecules has been published (Clin Chem 2009;55:1484-91). A report on the collaborative study to establish the 5th WHO international standard for hCG has been submitted to the WHO-ECBS for consideration at their October 2009 meeting.

8.3.19 WG-HbA1c: The major work to establish an international reference system to standardize HbA1c has been completed. The priority now is the implementation of the IFCC recommendations for standardizing and reporting HbA1c results.

8.3.33 WG-STFT: The WG-STFT held a meeting July 2009 in conjunction with the AACC Annual Meeting in Chicago, IL (US). The manuscripts describing the results from the phase I study are being revised for submission to Clinical Chemistry.

8.3.35 WG-HbA₂: The WG-SHbA₂ met June 2009 in Innsbruck, Austria. The preparation of the large final batches of the reference material for HbA₂ at the IRMM will be delayed until the candidate reference method is well defined.

8.3.36 WG-CDT: The WG-CDT met June 2009 in Innsbruck, Austria. The results of the CDT Ring Trial-A where a total of 12 laboratories (6 belonging to WG members and 6 to CDT companies) participated were reviewed. Two lyophilized and two ready-for-use (frozen) serum samples had been distributed and run by methods based on HPLC (the candidate reference method and 3 commercial assays), capillary electrophoresis (2 commercial assays), and immunochemistry (1 commercial assay). The CDT values generated by different analytical techniques, and also some results for assays using the same technology, produced markedly different results.

8.3.37 WG-SCC: The WG-SCC met June 2009 in Innsbruck, Austria. The concentration of cystatin C in the Primary Reference Preparation (PRP), as determined by dry mass analysis, is 5.1971 g/L, with an uncertainty of 0.0033 g/L. The value assignment of cystatin C in the Secondary Reference Preparation has been carried out using the above-mentioned PRP.. Work is underway to develop a more general cystatin C-based GFR-prediction equation.

8.3.38 WG-GFRA: There was concern about duplication of the terms of reference of the WG-GFRA with the Integrated Projects Task Force on Chronic Kidney Disease (TF-CKD). New terms of reference for the WG-GFRA were prepared. A study of creatinine assay specificity continues.

8.3.39 WG-SAU: A joint meeting of the WG-SAU, NKDEP LWG, and the WG-GFRA was held July 2009 in conjunction with the AACC Annual Meeting in Chicago, IL.

The status for each of the following projects was reported: 1 urine albumin adsorption study and albumin variability in urine, 2. urine albumin and creatinine reference materials, 3. urine albumin IDMS candidate reference measurement procedure.

8.3.40 WG-PAPPA: The WG-PAPPA met June 2009 in Innsbruck, Austria. A proposed plan for standardization of PAPPA was established with results of the first phase expected to be available in January 2010.

8.3.41 WG-GH: No meeting was planned in Innsbruck, Austria during EuroMedLab.

8.3.42 WG-SIA: Funding was provided by NIH to support the collection and preparation of a panel of single donor samples for insulin assay harmonization.

8.3.43 WG-TnI: The WG-TNI met July 2009 in conjunction with the AACC Annual Meeting in Chicago, IL (US). The pilot cardiac troponin I method comparison and commutability study to compare a candidate secondary immunoassay reference measurement procedure for cardiac troponin I with commercial assays and to investigate the feasibility of preparing a commutable secondary reference material for cTnI by use of serum pools will begin in 2010.

8.8 PROJECT PROPOSALS:

The IFCC EB approved the creation of the “WG on Allowable Errors for Traceable Results” (WG-AETR) 8.3.44.

8.19 MEETINGS

8.19.45 45th SD meeting, Corfu, Greece, April 16-17, 2010

8.19.46 46th SD meeting, Seoul, Korea, October 2-3, 2010.